Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.

Abstract	We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development.
Authors	G Tagliabue, S Filippeschi, H Hendricks, M D'Incalci
Journal	Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 3 Issue 3 Pg. 233-6 (Mar 1992) ISSN: 0923-7534 [Print] England
PMID	1586622 (Publication Type: Comparative Study, Journal Article)
Chemical References	Bridged Bicyclo Compounds Bridged Bicyclo Compounds, Heterocyclic Quaternary Ammonium Compounds NSC 262266 Cyclophosphamide
Topics	Animals Bridged Bicyclo Compounds (pharmacology) Bridged Bicyclo Compounds, Heterocyclic Cell Division (drug effects) Cyclophosphamide (pharmacology) Drug Administration Schedule Drug Resistance Female Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology) Mice Mice, Inbred C57BL Neoplasm Transplantation Quaternary Ammonium Compounds (pharmacology) Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!